Global Increlex Report 2025, Forecast To 2034
11 Mar, 2025
What Has Been the Growth of the Increlex Market So Far?
The increlex market has seen considerable growth due to a variety of factors.
• The size of the Increlex market, recently showing a CAGR of XX%, is projected to escalate from $XX million in 2024 to $XX million in 2025, marking a compounded annual growth rate of XX%.
Several factors can be attributed to the growth witnessed in the historic period, including an increased frequency of growth hormone insensitivity syndrome (GHIS) and pediatric growth hormone deficiency (PGHD). A rise in the occurrence of endocrine disorders, supportive government policies, and heightened awareness of rare pediatric endocrine disorders also play a crucial role.
What Are the Future Growth Projections for the Increlex Template Market?
The increlex market is expected to maintain its strong growth trajectory in upcoming years.
• Expectations are that the increlex market size will witness a XX FCAGR over the forthcoming years, escalating to a value of $XX million in 2029, with a compound annual growth rate (CAGR) at XX%.
The anticipated growth during the forecast period may be linked to the surging demand for effective therapies for growth hormone insensitivity, the increasing prevalence of personalized medicine, expanding clinical trials to widen therapeutic uses, rising regulatory approvals for novel formulations, the expansion of healthcare infrastructure in developing countries, and heightened global awareness of pediatric growth disorders. The significant trends for the forecast period consist of progress in recombinant DNA technology, enhancements in subcutaneous injection delivery systems, advances in patient surveillance solutions, integration of telemedicine for patient revisit, and progress in drug distribution systems.
What Are the Critical Driver Fuelling The Increlex Market's Growth?
The growth of the Increlex market is projected to accelerate due to an increase in the incidence of childhood-onset growth hormone deficiency (CGHD). CGHD is a condition in which a child's body fails to generate sufficient growth hormone, resulting in decelerated growth and decreased height. This surge in CGHD can be attributed to several factors, such as improvements in diagnosis techniques and heightened awareness about the condition. Consequently, increased awareness and diagnosis of CGHD are catalyzing the demand for Increlex, a synthetic IGF-1 remedy, thereby expanding the market as more children begin appropriate treatment. For example, as reported by the Council of Health Insurance in Saudi Arabia in November 2023, it is estimated that CGHD impacts between 1 in 3,500 to 1 in 10,000 children, with a noteworthy prevalence in boys. Therefore, the growing incidence of CGHD is directly contributing to the expansion of the Increlex market.
What Are The Major Segments Within The Global Increlex Market?
The increlex market covered in this report is segmented –
1) By Age Group: Infants, Toddlers, Children Aged 5-12 Years
2) By Distribution Channel: Hospitals, Specialty Clinics, Online Pharmacies, Pharmacies
3) By Application: Growth Hormone Deficiency, Other Indications
Who Are the Key Players In The Increlex Market?
Major companies operating in the increlex market are:
• Ipsen S.A
What Is The Most Dominant Region In The Increlex Market?
North America was the largest region in the increlex market in 2024. The regions covered in the increlex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.